Equity Profile

ERAS

Erasca, Inc.

Health CareBiotechnology$5.5B

Aug12Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Erasca, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment....

Key Metrics to Watch

EPS

Earnings per share will indicate the company's profitability and financial health.

N/A

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ERAS Q2-2026 Earnings Preview

Context

Company Snapshot

Erasca, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment. With a market cap of $6 billion, it operates in the healthcare sector, addressing significant medical needs in oncology.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

-29.90%

Avg Stock Reaction

+1.89%

Last Quarter Recap

In Q1-2026, Erasca reported an EPS of -$0.60, missing analyst expectations significantly. The stock reacted positively the following day, gaining 3.16%.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautious ahead of Erasca's earnings report, given the company's recent performance and lack of analyst estimates. The market is watching closely for any signs of improvement.

Bull Case

If Erasca can show a smaller loss than expected or positive developments in its drug pipeline, it could boost investor confidence and drive the stock higher.

Bear Case

Conversely, if the company reports a larger loss or fails to provide clarity on its future prospects, it could lead to a significant drop in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS figure be for Q2-2026?

The EPS result will be a key indicator of the company's financial performance and could significantly influence investor sentiment.

How much has the company spent on R&D in the last quarter?

R&D spending is crucial for future growth in biotech; higher spending could indicate confidence in upcoming products.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating the potential for Erasca to reduce its losses significantly this quarter, given its focus on innovative cancer treatments.

Supporting Evidence

The company's recent pipeline developments suggest a stronger future outlook than reflected in current estimates.

Options pricing indicates a larger expected move, suggesting that traders anticipate significant news or changes.

Key Risk

If the EPS comes in below -$0.50, it could undermine the bullish narrative.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it follows a significant earnings miss, and investors are looking for signs of recovery.

Bull Confirmed If

An EPS loss of less than -$0.50 would confirm the bull case and suggest improving financial health.

Bear Confirmed If

An EPS loss greater than -$0.60 would confirm the bear case and raise concerns about the company's viability.

Pre-Earnings Positioning

Options Market

Implied Move

±42.13%

Historical Avg

±5.3%

Pricing rich

The options market is pricing in a significant move, indicating heightened volatility expectations around the earnings report.

Options are pricing ±42.1% while ERAS has averaged ±5.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

215.7%

Calls (25K)P/C Ratio: 0.16Puts (5K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Erasca beats expectations, history suggests the stock could rise by around 5.3%, confirming a positive trend.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further clarity.

Miss

If the company misses again, history suggests a potential drop of around 7.8%, raising concerns about its future.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the drug pipeline and upcoming clinical trials.
2Details on R&D spending and its impact on future growth.
3Management's outlook on market conditions and competitive landscape.
4Insights into partnerships or collaborations that may enhance product development.
5Responses to questions about the recent earnings miss and plans to address it.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug10

BWBMO

Babcock & Wilcox Enterprises, Inc.

PreviewView

Aug10

ROIVBMO

Company Snapshot

Erasca, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment....

Key Metrics to Watch

EPS

Earnings per share will indicate the company's profitability and financial health.

N/A

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ERAS Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

-29.90%

Avg Stock Reaction

+1.89%

Last Quarter Recap

In Q1-2026, Erasca reported an EPS of -$0.60, missing analyst expectations significantly. The stock reacted positively the following day, gaining 3.16%.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautious ahead of Erasca's earnings report, given the company's recent performance and lack of analyst estimates. The market is watching closely for any signs of improvement.

Bull Case

If Erasca can show a smaller loss than expected or positive developments in its drug pipeline, it could boost investor confidence and drive the stock higher.

Bear Case

Conversely, if the company reports a larger loss or fails to provide clarity on its future prospects, it could lead to a significant drop in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS figure be for Q2-2026?

The EPS result will be a key indicator of the company's financial performance and could significantly influence investor sentiment.

How much has the company spent on R&D in the last quarter?

R&D spending is crucial for future growth in biotech; higher spending could indicate confidence in upcoming products.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating the potential for Erasca to reduce its losses significantly this quarter, given its focus on innovative cancer treatments.

Supporting Evidence

The company's recent pipeline developments suggest a stronger future outlook than reflected in current estimates.

Options pricing indicates a larger expected move, suggesting that traders anticipate significant news or changes.

Key Risk

If the EPS comes in below -$0.50, it could undermine the bullish narrative.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it follows a significant earnings miss, and investors are looking for signs of recovery.

Bull Confirmed If

An EPS loss of less than -$0.50 would confirm the bull case and suggest improving financial health.

Bear Confirmed If

An EPS loss greater than -$0.60 would confirm the bear case and raise concerns about the company's viability.

Pre-Earnings Positioning

Options Market

Implied Move

±42.13%

Historical Avg

±5.3%

Pricing rich

The options market is pricing in a significant move, indicating heightened volatility expectations around the earnings report.

Options are pricing ±42.1% while ERAS has averaged ±5.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

215.7%

Calls (25K)P/C Ratio: 0.16Puts (5K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Erasca beats expectations, history suggests the stock could rise by around 5.3%, confirming a positive trend.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further clarity.

Miss

If the company misses again, history suggests a potential drop of around 7.8%, raising concerns about its future.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the drug pipeline and upcoming clinical trials.
2Details on R&D spending and its impact on future growth.
3Management's outlook on market conditions and competitive landscape.
4Insights into partnerships or collaborations that may enhance product development.
5Responses to questions about the recent earnings miss and plans to address it.